Mounjaro prices hike sees patients switch to cheaper Wegovy
There has also been issues with some pharmacies running out of stock of Moumjaro, as patients try to get supplies before the price hike.
Mounjaro users report surprising side effect - pharmacists share their tips https://t.co/JecEW84Ifj — Bucks Free Press (@bucksfreepress) August 8, 2025
'With Mounjaro's price rise looming, it's not surprising that patients are exploring alternatives," says Jason Murphy, Head of Pharmacy at Chemist4U.
"Wegovy offers a safe, less expensive and almost equally effective weight loss solution and is a very good option to consider if Mounjaro becomes unaffordable.
'However, switching should always be as part of a conversation with your pharmacist or GP. Our role is to guide patients through the process, tailoring advice to their health history, so they can continue their weight loss journey with confidence.'
Both medications are part of a group called GLP-1 receptor agonists
What is Wegovy? Is it the same as Ozempic?
Wegovy and Mounjaro are both weekly injections originally designed for type 2 diabetes but are powerful weight-loss drugs. Wegovy (the brand name for semaglutide) works by mimicking a gut hormone (GLP-1) that curbs appetite and slows digestion. Semaglutide is also branded as Ozempic for managing type 2 diabetes, but is not prescribed for weight-loss in the UK.
Mounjaro goes a step further by also targeting a second hormone, GIP.
'When moving from Mounjaro to Wegovy, it's not a one-size-fits-all process," says Jason.
"Your starting Wegovy dose should always reflect the Mounjaro dose you were previously on, alongside your overall health, and how well you tolerated treatment. That's why a pharmacist's review is essential; it ensures the transition is safe, effective, and tailored to your individual needs.'
Who is eligible for Wegovy?
For those who have not taken a weight loss injection before, Wegovy has the same eligibility criteria as Mounjaro.
This means a BMI of 30 or higher, or a BMI of 27 or higher with a pre-existing medical condition that is affected by weight (e.g., cardiovascular disease or high blood pressure).
This might be more complicated for patients who have already lost weight on Mounjaro and are now below a BMI of 30, or 27, and now looking to continue their weight-loss, but experts recommend speaking a doctor or pharmacist.
How do you switch from Mounjaro to Wegovy?
Jason says that when switching, it's important to not stop Mounjaro until your prescriber confirms the switch to Wegovy is possible.
But, he cautions: 'Please note that the manufacturer recommends leaving 30 days from your last dose of Mounjaro and your first dose of Wegovy, to further reduce the risk of side effects, however we understand this could result in stalling your weight loss journey or potential weight gain.'
He adds that if you've already lost weight while taking Mounjaro, or are using it to maintain your weight, and are now below the eligibility criteria, you may still be able to switch to Wegovy; a clinical team will review your medical history and decide if it's safe and suitable.
Recommended reading:
What are the Wegovy and Mounjaro side effects?
People respond to medications in different ways, and even though Mounjaro and Wegovy share similar ingredients, some people may tolerate one better than another.
Jason adds: 'There are no 'withdrawal' symptoms in the usual sense. Some people notice their appetite increases as the medicine wears off, and any side effects usually settle after stopping. If you feel unwell or are unsure what to expect, speak to your prescriber.
'It's unlikely you'll gain weight when switching, as the effects of Mounjaro will continue during the seven days after your final dose. You will then immediately start taking Wegovy, which will continue to work in the same way. This means you can continue losing weight while switching, especially if you're sticking to your diet and exercise plan.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
an hour ago
- Scottish Sun
I lost 3.5st without fad diets or Ozempic, here's how I got a toned tum after 2 C-sections without going to the gym
Read on for the best workout for weight loss WEIGH TO GO I lost 3.5st without fad diets or Ozempic, here's how I got a toned tum after 2 C-sections without going to the gym Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A MUM has shared how she finally got a toned stomach after having two C-sections, without using Ozempic or fad diets. Bethanie Kendra, from the UK, revealed her top weight loss tricks and the one exercise that finally got rid of her lower stomach. Sign up for Scottish Sun newsletter Sign up 2 Bethanie Kendra shared how she lost weight and toned up after two C-sections Credit: tiktok/@bethaniekendra 2 I lost 3.5st without fad diets or Ozempic – Pilates finally got me my toned tum back after 2 C-sections, , TAKEN WITH NO PERMISSION:, Credit: tiktok/@bethaniekendra In the clip, she shared before and after images of her stomach which was now toned and slender. She said the first thing you had to do was lose weight, and she was able to shed 3.5 stone. "The only way you can lose weight is a calorie deficit. You want to focus on nutrition and diet, nutrition and diet, nutrition and diet," she explained Bethanie focused on whole foods, high protein, fibre and healthy fats rather than trying to stick to a fad diet. READ MORE WEIGHT LOSS STORIES NO WEIGH I lost 18st without fat jabs - I didn't cheat my way to new body by using Ozempic Next, the mum-of-two revealed she focused on doing pilates with some light weights. Pilates focuses on strength training, especially the core, which helps tone the stomach. "As somebody who has lost and gained a lot of weight three times, twice from having children and I've had two caesareans, I can honestly say Pilates, after the fat loss, is what has really toned up my stomach and build it out with definition and muscle," Bethanie added. "Almost everything is working your core and it focuses a lot on breathing and I don't think we realise, generally speaking, how important breathing is to activate and engage your core, your deep core properly." The best part is that Bethanie didn't have to leave the house to get her workout done as she used online pilate workouts on YouTube. Bethanie added in the comments section that the only other form of workouts she did to lose weight and maintain was to make sure she got 10,000 steps in a day. I'm a personal trainer - these 5 at-home core slider exercises mimic reformer Pilates (1) She said: "To lose the weight, yes, I did do cardio and now I do 10k minimum steps a day & 2 heavier cardio days a week." She added that heavier cardio includes doing the stair master or an incline walk on the treadmill. The clip posted to her TikTok account @bethaniekendra soon went viral with over 87k views and people were quick to thank her for the weight loss advice. One person wrote: "I did my first Pilates with Izzy this morning after your recommendation and loved it, I'm looking forward to getting up early and doing day 2. Thank you for inspiring me." Another commented: "You've inspired me to do at-home Pilates. The fact you do most things from home just proves you don't need the best membership to get these goals like I always thought you did. I hate going to the gym." "Me too! Lost 13kgs doing Pilates only and just recently joined the gym as I hit a bit of a plateau so needed to ramp it up a bit," penned a third. The 5 best exercises to lose weight By Lucy Gornall, personal trainer and health journalist EXERCISE can be intimidating and hard to devote yourself to. So how do you find the right workout for you? As a PT and fitness journalist, I've tried everything. I've taken part in endless fitness competitions, marathons and I maintain a regime of runs, strength training and Pilates. Fitness is so entrenched in my life, I stick to it even at Christmas! The key is finding an activity you love that can become a habit. My top five forms of exercise, especially if you're trying to lose weight, are: Walking Running Pilates High-intensity interval training (HIIT) Strength training Meanwhile a fourth said: "Needed a proper explanation and you did it brilliantly!" "Yesss it's amazing to see people losing weight the right way. Each to their own but I'm fed up of seeing everyone doing Mounjaro. Good for you,' claimed a fifth. Someone else added: "Couldn't agree more about calorie deficit and nutrition. Interesting that you've achieved such amazing results with Pilates!"
Reuters
2 hours ago
- Reuters
Telehealth's GLP-1 boom: balancing obesity care with HIPAA and state consumer privacy laws
August 20, 2025 - Demand for GLP-1 agonists, such as semaglutide and tirzepatide, exploded in 2024 and shows no signs of slowing in 2025. It is forecasted that the U.S. market will top $30 billion by the end of 2025 aided by physical brickandmortar clinics and national telehealth startups that offer fast online consults and front door delivery. The digital channel is attractive to patients as it allows for convenience and secrecy, including no waiting room, discreet shipping. As for providers, they can scale nationally. However, that same frictionless nationwide telehealth model magnifies privacy and cybersecurity risks. Online GLP-1 programs necessarily collect sensitive health histories, biometric data (such as weight, blood glucose levels, and sleep patterns), insurance details, and payment information. With that collection most providers embed advertising pixels to fuel customer acquisition. When that data straddles HIPAAregulated and consumerapp environments, the legal landscape quickly becomes treacherous. GLP-1 telehealth services almost always involve a "covered entity" (the clinician or pharmacy) plus multiple "business associates" (video visit platforms, fulfillment pharmacies, labs, and cloud vendors). Classic HIPAA safeguards therefore apply, which include encryption in transit and at rest, unique user IDs, role-based access, audit trails, and a written business associate agreement (BAA) with each vendor. Two federal developments heighten enforcement pressure: (1) Trackingtechnology bulletin: In March 2024, HHS OCR revised its 2022 guidance "Use of Online Tracking Technologies by HIPAA Covered Entities and Business Associates" clarifying that website cookies, pixels, and similar tools may transmit protected health information (PHI) when they identify a user as a patient, even if no appointment is booked. The Texas federal court decision, Am. Hosp. Ass'n v. Becerra, ---- F. Supp. 3d ----, No. 4:23-cv-1110, 2024 WL 3075865 (N.D. Tex. June 20, 2024), which vacated parts of the bulletin, created uncertainty, but OCR has reiterated that "regulated entities are not off the hook." The decision vacated only OCR's "proscribed combination" theory, that an IP address plus a visit to an unauthenticated health webpage is IIHI/PHII, leaving uncertainty about what, if any, other public-page interactions may trigger HIPAA duties when tracking tools are used. Because the rest of OCR's bulletin remains operative, especially for authenticated portals, and OCR continues to warn that disclosures of PHI to tracking vendors can violate HIPAA, entities must navigate unclear lines on public sites even as core obligations persist. (2) GoodRx's settlement consequences: The FTC's Complaint against GoodRx sent shockwaves through the healthcare industry as it was the first time the FTC had sought to use the Health Breach Notification Rule (the HNBR) (and parallel Section 5 order) against a healthcare provider. 15 U.S.C. § 45(a)(1). The FTC's Complaint alleged that GoodRx repeatedly violated these promises by sharing sensitive user information with third-party advertising companies and platforms, such as Google, Facebook and others. Specifically, GoodRx shared user prescription medication information, personal health conditions, personal contact information, and unique advertising and persistent identifiers without providing notice to the users and without first obtaining user consent to the sharing. Worse, the FTC Complaint alleged that GoodRx's sharing this information allowed the third parties to make profit from the information and use it for their own business purposes, including by using the information to personally target the users with advertisements. The suit resulted in a $1.5 million fine and a multi‑year ban on advertising using health data demonstrating the significant legal landmines when mixing telehealth services with ad retargeting. With this, OCR has indicated that it will treat similar pixel leaks as reportable breaches under HIPAA. In addition to HIPAA, 19 states, with more on the way, have comprehensive privacy laws in effect or scheduled, and several include "consumer health data" (CHD) that reaches beyond HIPAA. Three statutes matter most to GLP‑1 telehealth ventures: •Washington My Health My Data Act (MHMDA): The MHMDA covers any information "reasonably linked" to physical or mental health, including attempts to seek care, and those parts go into effect March 31, 2024 for large entities and on June 30, 2024 for small entities. The MHMDA also bans geofencing near abortion or gender‑affirming clinics and requires a signed consumer consent for CHD sharing or sale. The law also requires a signed consumer consent for CHD sharing or sale. •California Confidentiality of Medical Information Act (CMIA): The CMIA covers "Medical Information" held by any business that offers a digital health service to manage a medical condition. As expanded by AB 2089, CMIA treats telehealth weight‑management apps as "providers of health care," triggering HIPAA‑like security, access, and disclosure rules. •Florida Digital Bill of Rights (FDBR): The FDBR covers sensitive personal data, which expressly includes biometric and genetic data, and prohibits the offshoring of specific patient data and grants Floridians deletion, correction, and opt-out rights that rival those of the California Privacy Rights Act (CPRA). The FDBR also grants Florida residents deletion, correction, and opt-out rights, similar to those contained in the California Privacy Rights Act. Both CMIA and MHMDA authorize statutory damages in the amounts of $1,000 to $25,000 per violation. Plaintiffs have already alleged that pixel deployments disclose "health conditions" (obesity) and "treatment" (semaglutide) without consent, and parallel class actions under CPRA's "unauthorized disclosure" theory have been filed in California. Although GLP‑1s are not controlled substances, individual states regulate tele‑prescribing differently. Roughly one‑third require an in‑person visit before issuing an initial prescription, with Arkansas and Alabama tightening their rules this year. The issue gets even more complicated when a prescribing clinician is licensed in one state, the patient resides in another, and the compounding pharmacy is also in another because each state's respective telehealth practice laws (and privacy statute) follow with the data, meaning providers must ensure they have robust credentialing workflows and conduct conflict‑of‑law analyses before doing business or taking patients in new jurisdictions. From a privacy perspective, the shift pushes more patient data into electronic prescribing and REMS-style safety programs (Risk Evaluation and Mitigation Strategy), escalating HIPAA exposure. In response, it is recommended that telehealth platforms: (1) Map your tech stack. Take an inventory of every system that touches patient data, including intake forms, analytics, coaching apps, pharmacy routing, SMS, and reporting and identify was is covered entity, business associate or neither. Build a data flow diagram as it you would have to provide it to a regulator. (2) Minimize. For every data pathway on marketing sites and patient portals, disable non‑essential trackers by default, and negotiate "qualified service provider" status (with HIPAA‑style contractual limits) for analytics vendors that must remain; (3) Update privacy notices. Update Notice of Privacy Practices (NPP) to reflect any new manufacturer datasharing obligations. (4) Ensure vendor contract management. Reevaluate BAAs with compounding pharmacies that pivot to 503A, where prescriptions must be individually tied to a named patient. This may include adding contract indemnities for off label promotion claims that may surface in data sharing litigation with compounding pharmacies that pivot to 503A, where prescriptions must be individually tied to a named patient. This may include adding contract indemnities for off label promotion claims that may surface in data sharing litigation. (5) Implement specific jurisdictional toggles. Because GLP-1 telehealth companies frequently market nationwide, they must implement specific jurisdictional toggles in order to ensure compliance, for instance, turning off cross-site tracking for state-specific IP addresses unless express opt-in consent is obtained. (6) Pixel governance program. Apply an enterprise tracker inventory, run staticsite scans after each code push, and memorialize pixel risk assessments in HIPAA securityrule documentation. (7) Dynamic consent flows. Deploy geolocation logic to trigger "affirmative written consent" dialogs and suppress the session until accepted. (8) Tier vendors. Classify suppliers as HIPAA business associates, state CHD processors, or ordinary service providers. Flow down statespecific clauses, e.g., no "sale" or "share" of Washington CHD, right to delete Florida data within 45 days. (9) Boardlevel metrics. Track monthly privacy Key Performance Indicators (KPIs), including number of tracker removals, PHI access exceptions, deletionrequest turnaround, alongside clinical outcomes. GLP1 telehealth programs promise significant transformative benefits for millions living with obesity, yet the data they harvest is among the most sensitive in the digital economy. HIPAA remains the foundation, but a rapidly growing patchwork of state consumer healthprivacy statutes and federal enforcement actions dictate the contours of lawful virtual care. The healthcare providers that succeed will treat privacy not as a backoffice compliance task but as a strategic differentiator to build patient trust through transparency, minimize data collection, and ensure rigorous vendor oversight. Sara H. Jodka is a regular contributing columnist on privacy and data security for Reuters Legal News and Westlaw Today.
Economist
2 hours ago
- Economist
Devi Sridhar: living a long life isn't a solo endeavour
How long you live may be shaped less by your gym routine or diet plan than by the systems that surround you, from clean air and water to safe streets and accessible healthcare. In this episode, Devi Sridhar, a professor of global public health at the University of Edinburgh, argues that governments—not individuals—hold the greatest power to extend lives. She explains what people can learn from long-lived communities in Japan and Europe, how to curb the harms of ultra-processed food, the role of GLP-1 weight-loss drugs, and how tackling inequality could help everyone live healthier into old age. Alok Jha, The Economist 's science and technology editor, speaks with Devi Sridhar, the author of 'How Not to Die (Too Soon)'.
